login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Medindia »
Consumer Health »
Health Information »
Latest Publication and Research on Malignant Mesothelioma
| Disease Info Index | ||||||||||||||||||||||||||
|
|
Malignant Mesothelioma
Page Options
Drugs For Malignant Mesothelioma
Mesothelioma Cancer - Mesothelioma Facts - Malignant Mesothelioma
Latest Publication and Research on Malignant Mesothelioma
|
|
|
Text 
|
2011 Dec 5 Downregulation of MUC1 expression and its recognition by CD8(+) T cells on the surface of malignant pleural mesothelioma cells treated with HDACi. Roulois D, Blanquart C, Panterne C, Gueugnon F, Grégoire M, Fonteneau JF INSERM, U892, Institut de Recherche Thérapeutique de l'Université de Nantes, France; Université de Nantes, Faculté de médecine, France. Research into new treatments against malignant pleural mesothelioma (MPM) is of great interest, as this aggressive cancer is often resistant to conven... Read More Source: PubMed Int J Clin Exp Pathol ß-catenin expression in benign and malignant pleural disorders. Anani W, Bruggeman R, Zander DS Benign and malignant pleural processes display a large and overlapping spectrum of morphological appearances, and can be difficult to distinguish, his... Read More Source: PubMed 2011 Dec 1 Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Damhuis RA, Schroten C, Burgers JA P.O. Box 289, 3000 AG Rotterdam, The Netherlands. Malignant mesothelioma is known for its dismal prognosis and poor response to conventional treatment. Chemotherapy with cisplatin-antifolate combinati... Read More Source: PubMed 2011 Dec 1 The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. Erculj N, Kovac V, Hmeljak J, Franko A, Dodic-Fikfak M, Dolžan V aPharmacogenetics Laboratory, Faculty of Medicine, Institute of Biochemistry, University of Ljubljana bInstitute of Oncology Ljubljana cClinical Institute of Occupational Medicine, University Medical Centre, Ljubljana dCollege of Health Care Izola, University of Primorska, Izola, Slovenia. OBJECTIVE: Identification of biomarkers that could predict gemcitabine efficacy and toxicity is a key issue in the development of individualized thera... Read More Source: PubMed 2011 Nov 29 National survey of malignant mesothelioma and asbestos exposure in Japan. Gemba K, Fujimoto N, Kato K, Aoe K, Takeshima Y, Inai K, Kishimoto T Department of Respiratory Medicine, Okayama Rosai Hospital, Okayama, Japan. Department of Radiology, Okayama University Hospital, Okayama, Japan. Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan. Department of Pathology, Hiroshima University Graduated School of Medicine, Hiroshima, Japan. We retrospectively investigated malignant mesothelioma (MM) cases in Japan. We extracted 6,030 cases of death due to MM between 2003 and 2008 to clari... Read More Source: PubMed Rev Mal Respir [Pleuro-pulmonary metastases from a malignant mesothelioma of the tunica vaginalis]. Pannier D, Caty A, Hysi I, Bouchindhomme B, Copin MC, Porte H, Dansin E Département de cancérologie générale, CLCC Oscar-Lambret, 3, rue Frédérique-Combenate, 59020 Lille cedex, France. Mesothelioma is a malignant tumour of the serous membranes that principally affects the pleura. Peritoneal, pericardial and tunica vaginalis mesotheli... Read More Source: PubMed Int J Bioinform Res Appl Processing and analysis of serum antibody binding signals from Printed Glycan Arrays for diagnostic and prognostic applications. Vuskovic MI, Xu H, Bovin NV, Pass HI, Huflejt ME Department of Computer Science, College of Science San Diego State University, San Diego, CA 92182, USA. Procedures for data preprocessing, quality control, data analysis, evaluation and visualization of the new high-throughput biomarker platform based on... Read More Source: PubMed 2011 Nov 20 Data-Driven Information Retrieval in Heterogeneous Collections of Transcriptomics Data Links SIM2s to Malignant Pleural Mesothelioma. Caldas J, Gehlenborg N, Kettunen E, Faisal A, Rönty M, Nicholson AG, Knuutila S, Brazma A, Kaski S Aalto University School of Science, Department of Information and Computer Science, Helsinki Institute for Information Technology HIIT, Helsinki, Finland. MOTIVATION: Genome-wide measurement of transcript levels is an ubiquitous tool in biomedical research. As experimental data continues to be deposited... Read More Source: PubMed 2011 Nov 18 Diffuse malignant peritoneal mesothelioma - An update on treatment. Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL Cancer Research Laboratories, Department of Surgery, St. George Hospital, Sydney, Australia; St. George Clinical School, University of New South Wales, Kogarah, Sydney, NSW 2217, Australia. Mesotheliomas are aggressive and lethal neoplasms arising from mesothelial cells lining the pleura, peritoneum, tunica vaginalis testis and pericardiu... Read More Source: PubMed 2011 Nov 17 Adiponectin Pathway Attenuates Malignant Mesothelioma Cell Growth. Niu K, Asada M, Okazaki T, Yamanda S, Ebihara T, Guo H, Zhang D, Nagatomi R, Arai H, Kohzuki M, Ebihara S Department of Internal Medicine and Rehabilitation Science, Tohoku University Graduate School of Medicine, Sendai, Japan; Division of Biomedical Engineering for Health & Welfare, Tohoku University Graduate School of Medicine, Sendai, Japan; Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan. Malignant mesothelioma (MM) is caused by exposure to asbestos. Because MM has a latency period, short survival time, and has a poor response to curre... Read More Source: PubMed 2011 Nov 29 National survey of malignant mesothelioma and asbestos exposure in Japan. Gemba K, Fujimoto N, Kato K, Aoe K, Takeshima Y, Inai K, Kishimoto T Department of Respiratory Medicine, Okayama Rosai Hospital, Okayama, Japan. Department of Radiology, Okayama University Hospital, Okayama, Japan. Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan. Department of Pathology, Hiroshima University Graduated School of Medicine, Hiroshima, Japan. We retrospectively investigated malignant mesothelioma (MM) cases in Japan. We extracted 6,030 cases of death due to MM between 2003 and 2008 to clari... Read More Source: PubMed Rev Mal Respir [Pleuro-pulmonary metastases from a malignant mesothelioma of the tunica vaginalis]. Pannier D, Caty A, Hysi I, Bouchindhomme B, Copin MC, Porte H, Dansin E Département de cancérologie générale, CLCC Oscar-Lambret, 3, rue Frédérique-Combenate, 59020 Lille cedex, France. Mesothelioma is a malignant tumour of the serous membranes that principally affects the pleura. Peritoneal, pericardial and tunica vaginalis mesotheli... Read More Source: PubMed Int J Bioinform Res Appl Processing and analysis of serum antibody binding signals from Printed Glycan Arrays for diagnostic and prognostic applications. Vuskovic MI, Xu H, Bovin NV, Pass HI, Huflejt ME Department of Computer Science, College of Science San Diego State University, San Diego, CA 92182, USA. Procedures for data preprocessing, quality control, data analysis, evaluation and visualization of the new high-throughput biomarker platform based on... Read More Source: PubMed 2011 Nov 20 Data-Driven Information Retrieval in Heterogeneous Collections of Transcriptomics Data Links SIM2s to Malignant Pleural Mesothelioma. Caldas J, Gehlenborg N, Kettunen E, Faisal A, Rönty M, Nicholson AG, Knuutila S, Brazma A, Kaski S Aalto University School of Science, Department of Information and Computer Science, Helsinki Institute for Information Technology HIIT, Helsinki, Finland. MOTIVATION: Genome-wide measurement of transcript levels is an ubiquitous tool in biomedical research. As experimental data continues to be deposited... Read More Source: PubMed 2011 Nov 18 Diffuse malignant peritoneal mesothelioma - An update on treatment. Mirarabshahii P, Pillai K, Chua TC, Pourgholami MH, Morris DL Cancer Research Laboratories, Department of Surgery, St. George Hospital, Sydney, Australia; St. George Clinical School, University of New South Wales, Kogarah, Sydney, NSW 2217, Australia. Mesotheliomas are aggressive and lethal neoplasms arising from mesothelial cells lining the pleura, peritoneum, tunica vaginalis testis and pericardiu... Read More Source: PubMed 2011 Nov 17 Adiponectin Pathway Attenuates Malignant Mesothelioma Cell Growth. Niu K, Asada M, Okazaki T, Yamanda S, Ebihara T, Guo H, Zhang D, Nagatomi R, Arai H, Kohzuki M, Ebihara S Department of Internal Medicine and Rehabilitation Science, Tohoku University Graduate School of Medicine, Sendai, Japan; Division of Biomedical Engineering for Health & Welfare, Tohoku University Graduate School of Medicine, Sendai, Japan; Department of Geriatrics and Gerontology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan. Malignant mesothelioma (MM) is caused by exposure to asbestos. Because MM has a latency period, short survival time, and has a poor response to curre... Read More Source: PubMed 2011 Dec 5 Downregulation of MUC1 expression and its recognition by CD8(+) T cells on the surface of malignant pleural mesothelioma cells treated with HDACi. Roulois D, Blanquart C, Panterne C, Gueugnon F, Grégoire M, Fonteneau JF INSERM, U892, Institut de Recherche Thérapeutique de l'Université de Nantes, France; Université de Nantes, Faculté de médecine, France. Research into new treatments against malignant pleural mesothelioma (MPM) is of great interest, as this aggressive cancer is often resistant to conven... Read More Source: PubMed Int J Clin Exp Pathol ß-catenin expression in benign and malignant pleural disorders. Anani W, Bruggeman R, Zander DS Benign and malignant pleural processes display a large and overlapping spectrum of morphological appearances, and can be difficult to distinguish, his... Read More Source: PubMed 2011 Dec 1 Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Damhuis RA, Schroten C, Burgers JA P.O. Box 289, 3000 AG Rotterdam, The Netherlands. Malignant mesothelioma is known for its dismal prognosis and poor response to conventional treatment. Chemotherapy with cisplatin-antifolate combinati... Read More Source: PubMed 2011 Dec 1 The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma. Erculj N, Kovac V, Hmeljak J, Franko A, Dodic-Fikfak M, Dolžan V aPharmacogenetics Laboratory, Faculty of Medicine, Institute of Biochemistry, University of Ljubljana bInstitute of Oncology Ljubljana cClinical Institute of Occupational Medicine, University Medical Centre, Ljubljana dCollege of Health Care Izola, University of Primorska, Izola, Slovenia. OBJECTIVE: Identification of biomarkers that could predict gemcitabine efficacy and toxicity is a key issue in the development of individualized thera... Read More Source: PubMed |
| Share it! |  |
 |
 |
 |
 |
 |
 |
|
|
Comment & Contribute
| Related Links | ||||||||||||
|
Medwonders Health Network
| Citing this Health Article | ||||||
|
||||||
| News on Malignant Mesothelioma |
Are you a member of Facebook? Become a fan of Medindia and get breaking news delivered to your Facebook page.
